NextFin News - On December 5, 2025, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus expressed strong optimism regarding the finalization of the Pathogen Access and Benefit-Sharing (PABS) system, a core and previously unresolved element of the landmark Pandemic Agreement. The agreement, brokered by WHO member states after over three years of post-COVID-19 negotiations, aims to create a comprehensive framework to prevent the fragmented global responses seen during the COVID-19 pandemic by facilitating coordinated surveillance, preparedness, and equitable access to vaccines, diagnostics, and treatments in future pandemics.
The PABS system specifically addresses the mechanisms for sharing access to pathogens of pandemic potential and the fair distribution of benefits derived from them, such as vaccines, diagnostic tests, and therapeutics. While the broader treaty was adopted in April 2025, this critical annex was deferred to allow additional time for resolution. Countries are now tasked to finalize negotiations by the WHO’s World Health Assembly scheduled for mid-May 2026, with talks resuming January 20-22, 2026. Consensus will enable the treaty’s ratification, which requires 60 countries to sign for entry into force.
Tedros described the completion of PABS negotiations as both a "generational opportunity and a generational responsibility," underscoring the global urgency to improve pandemic governance. Co-chairs of the talks, including Ambassador Matthew Harpur and Ambassador Tovar da Silva Nunes, echoed optimism about building a balanced framework that enables faster, fairer access and benefit-sharing across all nations.
This development is situated amid ongoing global political dynamics, including the United States under U.S. President Trump’s administration seeking to reaffirm leadership in pandemic response efforts while balancing national interests. Many countries express strong support for a multilateral system to avoid unilateral or bilateral deals that could undermine collective action and equity.
Analyzing the progress reveals multiple drivers: the devastating fragmentation and inequity during the COVID-19 pandemic accelerated international commitment to robust, binding frameworks ensuring timely pathogen sharing and vaccine access. The pandemic’s economic and social toll – with tens of millions of lives lost and GDP contractions exceeding 4% globally in some years – crystallized the need for treaty mechanisms that encourage transparency, rapid scientific exchange, and equitable benefit distribution to all countries regardless of economic status.
From an operational standpoint, the PABS system integrates pathogen sample sharing, genomic data exchange, and benefit-sharing protocols within one legal instrument designed to prevent delays previously seen when countries withheld pathogen access due to sovereignty or profit concerns. Yet, the complexity of balancing national sovereignty, intellectual property rights, and global public good motives poses negotiation challenges. WHO’s mandate, coupled with active engagement of regional blocs like the African Union, seeks to bolster governance frameworks addressing these issues.
Early modeling studies commissioned post-COVID-19 show that delays in vaccine access can cost hundreds of thousands of lives and billions in economic losses; for example, a one-month lag in pathogen genome data sharing during COVID-19 could have led to an excess 400,000 deaths globally. This amplifies the urgency to operationalize the PABS mechanism efficiently. The 100 Days Mission, supported by pharmaceutical industry stakeholders, aligns with these goals, seeking to have diagnostics, vaccines, and treatments ready within 100 days of outbreak identification.
Geopolitically, the treaty must navigate increasing bilateral pressures, where powerful countries pursue separate deals that risk fragmenting global solidarity. Notably, parts of Africa and other vulnerable regions advocate for binding guarantees ensuring they receive timely access to medical countermeasures from pathogen data derived in their countries. Continent-wide platforms are being developed to consolidate pathogen sharing and data governance, aiming to avoid pitfalls of past pandemics where vaccine nationalism caused wide disparities.
The forthcoming month-long negotiation rounds in January 2026 will be critical in closing gaps on modalities around intellectual property, benefit-sharing, swift pathogen access, and financial mechanisms to support equitable implementation. Once ratified, the treaty promises to recalibrate global pandemic preparedness governance, incentivize rapid data and biological sample sharing, and create mechanisms that bind participants to share benefits equitably, thus mitigating health and economic shocks of future crises.
Forward-looking, the treaty’s adoption and enforcement will likely catalyze enhanced investment in global health infrastructure, digital pathogen surveillance networks, and local manufacturing capacities in the developing world. Countries will likely establish more transparent and legally binding commitments reducing opportunities for exploitative bilateral agreements. More robust multilateralism around pathogen sharing could also stimulate innovation ecosystems by providing predictable access to pathogen data, accelerating vaccine development pipelines and lowering barriers to entry for smaller economies.
Nonetheless, success will depend on sustained political will, trust-building between nations, and effective WHO oversight amid competing national interests. The upcoming World Health Assembly and subsequent ratifications will be pivotal to observe whether the global community can institutionalize these pandemic preparedness gains or if geopolitical fissures will dilate, risking repetition of past inequities.
In sum, the WHO chief’s optimistic outlook reflects meaningful but cautious progress in finalizing the PABS system, a keystone in the new pandemic treaty architecture. This mechanism, by legally codifying pathogen access and equitable benefit-sharing, stands to transform global health security, enabling faster, fairer responses to future pandemics, healing wounds of COVID-19’s disparities, and protecting millions of lives worldwide.
Explore more exclusive insights at nextfin.ai.
